Matarin Capital Management’s Corcept Therapeutics CORT Stock Holding History

Matarin Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$6.27M	Sell	239,742 -122,755	-34%	-$2.59M	1.53%	2
2020 Q3	$6.31M	Sell	362,497 -47,833	-12%	-$762K	1.32%	2
2020 Q2	$6.9M	Sell	410,330 -213,585	-34%	-$3M	1.38%	4
2020 Q1	$7.42M	Sell	623,915 -26,360	-4%	-$326K	1.15%	7
2019 Q4	$7.87M	Sell	650,275 -241,361	-27%	-$3.36M	0.75%	47
2019 Q3	$12.6M	Buy	891,636 +161,448	+22%	+$1.98M	0.95%	22
2019 Q2	$8.14M	Buy	730,188 +466,792	+177%	+$5.2M	0.58%	72
2019 Q1	$3.09M	Buy	263,396 +163,367	+163%	+$2.03M	0.22%	148
2018 Q4	$1.34M	Buy	+100,029	New	+$1.32M	0.11%	190
2017 Q4	–	Sell	-20,832	Closed	-$402K	–	294
2017 Q3	$402K	Sell	20,832 -1,954	-9%	-$29.1K	0.03%	250
2017 Q2	$269K	Sell	22,786 -4,764	-17%	-$51.8K	0.02%	254
2017 Q1	$302K	Buy	+27,550	New	+$242K	0.03%	250

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Matarin Capital Management's CORT Position: Q4 2020 in Review

Matarin Capital Management reduced its Corcept Therapeutics (CORT) stake by 34% in Q4 2020, selling an estimated $2.59M and leaving 239,742 shares worth $6.27M. The position accounts for 1.53% of the portfolio, ranked #2.

Matarin Capital Management first reported a position in CORT in Q1 2017 and has held it in 12 quarters since. The position peaked at $12.6M in Q3 2019. 226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

Matarin Capital Management held 239,742 shares of Corcept Therapeutics worth $6.27M as of Q4 2020.
Matarin Capital Management sold 122,755 Corcept Therapeutics shares in Q4 2020, an estimated $2.59M.
Corcept Therapeutics made up 1.53% of Matarin Capital Management's portfolio in Q4 2020, its #2 holding.
Matarin Capital Management first reported a position in Corcept Therapeutics in Q1 2017 and has held it in 12 quarters since.
Matarin Capital Management's Corcept Therapeutics position peaked at $12.6M in Q3 2019.
226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.